Free tool
FAERS Monitor: Betoptic S
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019845 or its brand name (Betoptic S, Betaxolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
521
Serious
400
77% of reports
Hospitalization
242
Death reported
44
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall67
- dyspnoea61
- drug ineffective50
- pain39
- dizziness38
- asthma35
- eye irritation35
- fatigue34
- nausea33
- haemorrhage32
- headache31
- hypersensitivity31
- cardiac failure congestive30
- limb injury30
- wound30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 11 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 8 |
| 2009 | 11 |
| 2010 | 11 |
| 2011 | 13 |
| 2012 | 13 |
| 2013 | 10 |
| 2014 | 9 |
| 2015 | 14 |
| 2016 | 19 |
| 2017 | 37 |
| 2018 | 48 |
| 2019 | 64 |
| 2020 | 31 |
| 2021 | 24 |
| 2022 | 43 |
| 2023 | 31 |
| 2024 | 55 |
| 2025 | 26 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,638 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| limb injurySignal | 30 | 44.6 | 31.5 | 1,237 |
| woundSignal | 30 | 43.4 | 30.6 | 1,200 |
| eye irritationSignal | 35 | 24.6 | 17.8 | 769 |
| cardiac failure congestiveSignal | 30 | 15.1 | 10.7 | 382 |
| asthmaSignal | 35 | 12.5 | 9.1 | 361 |
| haemorrhageSignal | 32 | 12.4 | 8.8 | 324 |
| fallSignal | 67 | 8.1 | 6.5 | 418 |
| hypersensitivitySignal | 31 | 6.7 | 4.8 | 147 |
| dyspnoeaSignal | 61 | 4.4 | 3.4 | 158 |
| dizzinessSignal | 38 | 3.1 | 2.3 | 52 |
| painSignal | 39 | 2.6 | 1.9 | 37 |
| headache | 31 | 2.0 | 1.4 | 15 |
| fatigue | 34 | 1.8 | 1.3 | 11 |
| nausea | 33 | 1.7 | 1.2 | 9 |
| drug ineffective | 50 | 1.5 | 1.2 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.